GoAI
Get started
FunPep Company Limited logo

FunPep Company Limited

4881.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥50.00

+¥1.00 · +2.04%

Aug 25, 10:34 AM JST

4881.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Toshimi Miyoshi
Listed since
Dec 25, 2020
Employees
15

Market position

Day range

Current ¥50.00

52-week range

Current ¥50.00

Open
¥49.00
Previous close
¥49.00
Volume
34.1K
0.05× average
Average volume
676.6K
Average daily volume
Market cap
2.24B JPY
Beta
0.81
Market reference 1
50-day average
¥59.16
-15.48% below average
200-day average
¥76.62
-34.74% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.35B JPY
P/E (TTM)
-1.31×
P/B (TTM)
1.46×
P/S (TTM)
1,059.7×
EV / EBITDA
-0.84×
Earnings yield
-61.22%
Free cash flow yield
-44.45%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-962.10%
Operating margin
-60349.48%
Net margin
-74879.49%
Return on equity
-130.56%
Return on assets
-96.50%
Return on invested capital
-107.02%

Financial health

Debt / equity
0×
Current ratio
3.74×
Altman Z-score
1.61
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends60985%-182561%-426107%-669653%Gross margin, FY2021: 98.62%Gross margin, FY2022: -1203.28%Gross margin, FY2023: -8119.62%Gross margin, FY2024: -617.90%Gross margin, FY2025: -13240.45%Operating margin, FY2021: -587.25%Operating margin, FY2022: -109565.98%Operating margin, FY2023: -187567.36%Operating margin, FY2024: -14717.76%Operating margin, FY2025: -525053.50%Net margin, FY2021: -537.77%Net margin, FY2022: -109888.94%Net margin, FY2023: -176116.23%Net margin, FY2024: -14511.05%Net margin, FY2025: -608766.56%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 98.62%. Gross margin FY2022 -1203.28%. Gross margin FY2023 -8119.62%. Gross margin FY2024 -617.90%. Gross margin FY2025 -13240.45%. Operating margin FY2021 -587.25%. Operating margin FY2022 -109565.98%. Operating margin FY2023 -187567.36%. Operating margin FY2024 -14717.76%. Operating margin FY2025 -525053.50%. Net margin FY2021 -537.77%. Net margin FY2022 -109888.94%. Net margin FY2023 -176116.23%. Net margin FY2024 -14511.05%. Net margin FY2025 -608766.56%.

Income trends

Revenue

314K JPY-94.88%

Operating income

−1.65B JPY-82.83%

Net income

−1.91B JPY-115.00%
Income trends across reported periods330.71M JPY−484.65M JPY−1.3B JPY−2.12B JPYRevenue, FY2021: 126.87M JPYRevenue, FY2022: 1.07M JPYRevenue, FY2023: 530K JPYRevenue, FY2024: 6.13M JPYRevenue, FY2025: 314K JPYOperating income, FY2021: −745.04M JPYOperating income, FY2022: −1.17B JPYOperating income, FY2023: −994.11M JPYOperating income, FY2024: −901.76M JPYOperating income, FY2025: −1.65B JPYNet income, FY2021: −682.27M JPYNet income, FY2022: −1.17B JPYNet income, FY2023: −933.42M JPYNet income, FY2024: −889.09M JPYNet income, FY2025: −1.91B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 126.87M JPY. Revenue FY2022 1.07M JPY. Revenue FY2023 530K JPY. Revenue FY2024 6.13M JPY. Revenue FY2025 314K JPY. Operating income FY2021 −745.04M JPY. Operating income FY2022 −1.17B JPY. Operating income FY2023 −994.11M JPY. Operating income FY2024 −901.76M JPY. Operating income FY2025 −1.65B JPY. Net income FY2021 −682.27M JPY. Net income FY2022 −1.17B JPY. Net income FY2023 −933.42M JPY. Net income FY2024 −889.09M JPY. Net income FY2025 −1.91B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue314K JPY6.13M JPY530K JPY1.07M JPY126.87M JPY
Cost of goods sold41.89M JPY43.99M JPY43.56M JPY13.91M JPY1.75M JPY
Gross profit−41.58M JPY−37.86M JPY−43.03M JPY−12.84M JPY125.12M JPY
Research and development1.3B JPY537.99M JPY677.45M JPY908.68M JPY662.11M JPY
Selling, general, and administrative311.07M JPY295.47M JPY256.13M JPY247.55M JPY208.05M JPY
Operating expenses1.61B JPY863.9M JPY951.07M JPY1.16B JPY870.16M JPY
Interest income3.28M JPY170K JPY23K JPY29K JPY31K JPY
Depreciation and amortization41.89M JPY42.53M JPY43.56M JPY13.91M JPY1.37M JPY
Operating income−1.65B JPY−901.76M JPY−994.11M JPY−1.17B JPY−745.04M JPY
Net income−1.91B JPY−889.09M JPY−933.42M JPY−1.17B JPY−682.27M JPY

Company facts updated Aug 25, 2026.

Earnings

Latest EPS result
-5.63

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-4.79-9.61-14.43-19.25Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -6.29, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 12, 2025: actual -10.66, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -18.24, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 6, 2025: actual -6.91, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -7.99, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 12, 2026: actual -17.06, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual -7.03, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -5.63, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates3.24M2.17M1.11M44.2KQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q4 '25Q2 '26Q3 '26
Q2 2024, reported May 13, 2024: actual 414K JPY, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 8, 2024: actual 116K JPY, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 14, 2024: actual 3M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 12, 2025: actual 3M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 52K JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 262K JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual 52K JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 1M JPY, estimate —, surprise —, Comparison unavailable.

4881.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,936

-0.73%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,787

-0.17%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,670

-0.90%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,030

-1.47%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,826.5

-1.10%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,397

-0.39%

Continue in GoAI

Research 4881.T

research.disclaimer